Novel methylation gene panel in adjacent normal tissues predicts poor prognosis of colorectal cancer in Taiwan

Table 2 Relationship between the number of hypermethylated genes and 5-year time to progression of colorectal cancer patients, n (%)

	Normal tissues						Tumor tissues
	No. of subjects	No. of cases	Crude		Adjusted		No. of subjects	No. of cases	Crude		Adjusted
			HR	95%CI	HR	95%CI			HR	95%CI	HR	95%CI
NO. of hypermethylated genes
0	9	3 (33.3)	1.00	Referent	1.00	Referent	3	1 (33.3)	1.00	Referent	1.00	Referent
1	34	8 (23.5)	0.76	0.15-3.74	0.64	0.13-3.23	7	0 (0)	N/A	N/A	N/A	N/A
2	42	16 (38.1)	1.58	0.36-6.94	1.62	0.34-7.62	28	8 (28.6)	0.47	0.05-4.20	0.65	0.07-5.88
3	21	12 (57.1)	2.66	0.58-12.19	2.18	0.46-10.4	39	15 (38.5)	1.02	0.13-7.86	1.36	0.17-10.7
4	11	3 (27.3)	1.28	0.21-7.65	1.48	0.18-12.2	23	14 (60.9)	2.12	0.28-16.3	2.56	0.33-20.2
5	3	3 (100)	7.26a	1.00-52.84	4.70	0.57-39.0	17	6 (35.3)	1.17	0.14-9.71	1.52	0.17-13.5
6	0	0	N/A	N/A	N/A	N/A	3	1 (33.3)	1.13	0.07-18.0	2.10	0.12-38.3
P value1				0.02		0.02				0.02		0.02
≥ 3 of genes2	35	18 (51.4)	1.99a	1.03-3.85	2.01a	1.00-4.01	82	36(43.9)	3.26a	1.27-8.39	3.18a	1.21-8.39

¹P for trend.

²Including CDKN2A, hMLH1, MGMT, CSF2, DIS3L2, and OAF.

^aP < 0.05. Adjusted for gender, age at surgery (continuous), adjuvant chemotherapy, histological grade, and tumor location. CI: Confidence interval; HR: Hazard ratio; N/A: Not applicable.